AR and neoplasm: AR + /FOXA1 + expression defines a luminal-like TNBC subgroup with a worse outcome compared to other TNBC and a higher risk of late recurrences mimicking luminal tumours behaviour and suggesting a putative role for anti-androgen therapies.